Literature DB >> 31787557

TMS for staging and predicting functional decline in frontotemporal dementia.

Alberto Benussi1, Valentina Dell'Era1, Valentina Cantoni2, Maria Sofia Cotelli3, Maura Cosseddu4, Marco Spallazzi5, Anna Micheli6, Rosanna Turrone4, Antonella Alberici4, Barbara Borroni7.   

Abstract

OBJECTIVE: To evaluate if transcranial magnetic stimulation (TMS) measures correlate with disease severity and predict functional decline in frontotemporal dementia (FTD) phenotypes.
METHODS: Paired-pulse TMS was used to investigate the activity of different intracortical circuits in 171 FTD patients (122 bvFTD, 31 avPPA, 18 svPPA) and 74 healthy controls. Pearson's correlations were used to analyze the association between TMS measures and disease severity, while multiple regression analysis was used to identify the best clinical or neurophysiological measure to predict functional decline at 12 months.
RESULTS: We observed significant strong correlations between TMS measures [short interval intracortical inhibition-facilitation (SICI-ICF) and long interval intracortical inhibition (LICI)], and disease severity (evaluated with the FTLD-CDR) (all r > 0.5, p < 0.005). SICI-ICF, short interval intracortical facilitation (SICF) and LICI were also significant predictors of functional decline, evaluated as the change in FTLD-CDR scores at 12 months (all p < 0.005), while at the stepwise multiple regression analysis, SICI was the best predictor of disease progression, accounting for 72.5% of the variation in FTLD-CDR scores at 12 months (adjusted R2 = 0.72, p < 0.001).
CONCLUSIONS: The present study has shown that the dysfunction of inhibitory and facilitatory intracortical circuits, evaluated with TMS, correlates with disease severity and progression, accurately predicting functional decline at 12 months, better than any other investigated marker.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Frontotemporal dementia; Long interval intracortical inhibition; Prognosis; Progression; Short interval intracortical inhibition-intracortical facilitation; Transcranial magnetic stimulation

Year:  2019        PMID: 31787557     DOI: 10.1016/j.brs.2019.11.009

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  5 in total

1.  Transcranial stimulation in frontotemporal dementia: A randomized, double-blind, sham-controlled trial.

Authors:  Alberto Benussi; Valentina Dell'Era; Maura Cosseddu; Valentina Cantoni; Maria Sofia Cotelli; Maria Cotelli; Rosa Manenti; Luisa Benussi; Chiara Brattini; Antonella Alberici; Barbara Borroni
Journal:  Alzheimers Dement (N Y)       Date:  2020-05-27

Review 2.  Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration.

Authors:  Marcello Giunta; Eino Solje; Fabrizio Gardoni; Barbara Borroni; Alberto Benussi
Journal:  J Exp Pharmacol       Date:  2021-03-24

3.  Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease.

Authors:  Alberto Benussi; Valentina Cantoni; Mario Grassi; Lucie Brechet; Christoph M Michel; Abhishek Datta; Chris Thomas; Stefano Gazzina; Maria Sofia Cotelli; Marta Bianchi; Enrico Premi; Yasmine Gadola; Maria Cotelli; Marta Pengo; Federica Perrone; Maria Scolaro; Silvana Archetti; Eino Solje; Alessandro Padovani; Alvaro Pascual-Leone; Barbara Borroni
Journal:  Ann Neurol       Date:  2022-06-06       Impact factor: 11.274

4.  Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Alberto Benussi; Valentina Cantoni; Jasmine Rivolta; Silvana Archetti; Anna Micheli; Nicholas Ashton; Henrik Zetterberg; Kaj Blennow; Barbara Borroni
Journal:  Alzheimers Res Ther       Date:  2022-10-13       Impact factor: 8.823

5.  A Systematic Review of Long-Interval Intracortical Inhibition as a Biomarker in Neuropsychiatric Disorders.

Authors:  Parmis Fatih; M Utku Kucuker; Jennifer L Vande Voort; Deniz Doruk Camsari; Faranak Farzan; Paul E Croarkin
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.